<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 315 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page314.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=315">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 315 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 315</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=315"><img src="../thumb/315.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>278 / 2020-04                                                            Anti-Microbials - 18.12
   flush., flu-like sympts., pain, redistribut./ accumulat. of body fat, rais.  ther. Follow.recomm.dos.& monit.of other concom. antiretrovir.ther.  x2-3 wks. aft.vacc. & when admin.without vacc. treat.for durat.of
   ser.cholester.& triglycerid. conc., incr.tot.cholester.  Adults: Init 200 mg dly.x14 days (i.e. lead-in period) follow.by 200 mg   outbreak or approx.6 wks. Treatm: Init.within 48 hrs.of sympts.&
   Special precautions: Must not be used as monother. /add.on as   2xdly.in combinat.with at least two antiretrov.agents to which pt.not   cont.x4-5 days.
   sole agent to fail.regim., ser. nerv.syst.& psych.sympts.report., con-  prev. expos. to. Tot.dly.dos.not to exceed 400 mg.  Contraindications: Pregn., lactat., confus., hallucinat.or epileptif.
   sid.alternat. to clarithromycin, use barrier contracept.in combinat.   Contra-indications: Sev.hepat.dysfunct., Child-Pugh class B or   states, sev. ren./hepat.dis., glauc., childr.&lt;5 yrs.
   with other methods, teratogenic.report., pregn. test in women of   C, end-stage ren.fail. when pts.not haemodialys., AST/ALT &gt;5x up-  Side effects: Incr.seiz.freq., depress., anx., mood elev., agitat., nerv-
   childbear.potent.bef.init. ther., pass.into breast milk, recomm that   per lim. normality (ULN) until baseline AST/ALT stabilis. &lt;5 ULN,   ousn., hallucinat., nightmares, confus., disorientat., psychot.disord.,
   breast feed women do not breast feed their infants, ref.to prod. lit.  not to be re-admin.in cases of perman. discont.for sev.rash/ rash   delirium hypoman. state, mania, CNS effs.incl.dyskines., convuls.,
   when prescrib.other meds., consid. simultan. discont.of all antiret-  with constitut. sympts. /hypersens.syndr./clinic. hepatit., AST/  NMS-like sympt., periph./ankle oed., livedo reticularis, palpit., or-
   rovir.meds.if combinat. regim.is interrupt.because of suspect. intol.   ALT&gt; 5x ULN dur.ther.& had rapid recurr.of liv.funct.abnormalit.on   thostat.hypotens., card. insuff./ fail., leucopen., GI eff., skin reacts.
   & restart medicat.at same time upon resolut. of intol. sympts., in-  re-admin., safety in pregn.& lactat. not est., concom. ketocona-  incl. diaphores. & photosens., ocul.effs.incl.corn. epithel. oed.& vis.
   termitt.monother./sequent. reintroduct. not advis., discont.in sev.  zole & St. John’s Wort.  acuity, urin.retent./incont.
   rash & consid. prophylax.with appropr.anthistam./ corticoster. for   Side effects: Sev.& life threaten.skin reacts. incl.Stev.John.  Warnings and special precautions: Caref. monit. other anti-
   mild to mod.rash to improv.tol.& resolv. rash, be alert to psychos.-  syndr.& tox.epiderm.necrolys., hypersens.syndr.charact.by rash   parkinson.agents & epilept., incr. hallucinat./confus.& nightmare
   like reacts.& sev. ac. depress.reports, ment.illn./subst.abuse hist.,   with constitut. sympts., sev./life threaten.hepatotox.incl.fatal   poss,with concom. anticholin./underly.psychiatr.disords., pts.at-
   suicid.ideat./attempts.report., liv.dis., monit. liv. enzymes partic.in   fulmin.hepatit., somnol., bld.dyscras., allerg. reacts.incl.ana-  tempt. suic., grad.reduc., emergence of cross-resist. virus., no
   known/suspect.hepatit.B/C infect. hist./concom.hepatotox.meds.,   phylax., headache, GI disturbs., jaund., myalg., arthralg., fatig.,   stimul.agents (eg sympathomimet. /appetite-depress.) must be
   reg.monit.for jaund.(lab bilirub.&liv.enzym) & bleed.tendenc., immed.  fev., ren. dysfunct.  giv., early pregn., adeq. meas.to prev.pregn., CCF, sev.ren./hepat.
   discont.treatm./meds contain.efavirenz & monit pts for liv fail.for up   Special precautions: Careful monit.of pts. with pre-treatm. AST/  dis., recurr.eczema, gastr.ulcerat., CV disords., monit. pts.with pre-
   to 12 mnths., not recomm. in mod-sev.hepat.impairm., safety & effic.   ALT 2-3xULN for deteriorat. of liv.funct., adeq.contracept.other than   exist.seiz.disords.
                                                st
   in pts.with both HIV & hepatit.B not est., consid.cholestrol./trglyc-  hormon.in women, critic.to monit.1  18 wks.to identify sev.life-  Drug interactions: Incr.atropine-like S/E with anticholinerg.agents
   erides monit., use not assess.in paed.pts.bel.3 yrs./weigh. &lt;13 kg.  threaten.skin reacts./ ser.hepatit.or hepat.fail., discont.ther.if sev.   & levodopa, psychot. decompensat. with concom.neurolept.med./
   Drug interactions: Plasma conc.of other compds. that are metabol.  rash/rash accompan.by constitut.sympt., resist. virus emerg.with   levodopa, incr.CNS toxic.with CNS-act.substanc.& alcoh., clear.re-
   by CYP3A4 poss.decr., AUC & C max of indinavir/saquinavir & clarithro-  monother.theref.always admin. as combinat.ther., perman.discont.  duc.by hydrochlorothiaz.& K-spar. diurets.
   mycin decr., incr.freq.of S/E with ritonavir, rifampicin decr.AUC & C max   if hypersens.syndr.occurs/mod.to sev.LFT abnorm. detect., incr.  TAMIFLU, Roche [P/S]
   ,, methadone plasma lev.decr.result.in opiate withdr.signs in HIV in-  AST/ALT lev.&/ chron.hepatit.B&C co-infect.assoc.with great.risk   Oseltamivir
   fect.IV drug users, expect. reduc.plasma conc.with St John’s Wort.  of hepat.adverse events dur.antiretrovir.other. contain. nevirapine,   Indications: Treatm.of influenza in adults & childr.&gt; 1 yr, prophylax.
   SONKE LAMIVUDINE 150, (Sonke) Ranbaxy [P/S]  women at high.risk of develop.rash, interrupt.ther.in case of mod.   of influenza in adults & childr.&gt; 1 yr.
                                abnorm.liv.funct. tests & only re-introduc.at init.dos.once tests return
   Lamivudine                   to baseline, monit.liv.funct.prior to & at interv.dur.ther.& vigil.for pro-  Treatm.of infts. 6-12 mnths.of age dur.a pandemic influenza outbreak
   Indications: Part of anti-retrovir.combinat. ther. of HIV infect.  drom.signs of hepatit., opportunist.infects. & other complicat. of HIV   only, and not for endemic (season.) influenza use.
   adults & childr.             infect.may contin., concom.fluconazole, monit.prothromb.time with   (S4) CAPS, 42/20.2.8/1020, 1021, 40/20.2.8/0578
   (S4) TABS, A40/20.2.8/0272   concom.warfar.as coagulat.time may incr./ decr., alt.ther.to clarithro-  716752-001: 30 mg, 10, R203,95
   703378-001: 150 mg, 60, R44,40  mycin recom.in Mycobacterium avium-intracellular complex., if ther.  716751-001: 45 mg, 10, R387,53
   Dosage: Consult zidovudine P/I  interrup.for long. than 7 days restart with recomm. lead-in dos., sup-  705728-001: 75 mg, 10, R407,91
   Adults & adolesc.over 12 yrs: 300 mg dly admin.as sngl.dly dos   plem.nevirapine dos. follow.haemodialys.  (S4) ORAL SUSP, 47/20.2.8/1194
   or 150 mg 2xdly.             Drug interactions: Low.plasma conc.of concom. meds.metabol.  3000433-002: 6 mg/ml, 64,7 ml, R203,96
   Low bm(&lt;50 kg): Recomm.dos: 2 mg/kg 2xdly.  by CYP3A or CYP2B enzymes, saquinavir (hard gelatince caps) &   3000433-001: 6 mg/ml, 100 ml, R195,12
                              9
   Contra-indications: Abnorm.low neutrophil counts (&lt;0,75x10 /l)   indinavir lev. reduc., incr.plasma lev.with ketoconazole, nevirapine   Dosage: Admin.with food may enhance.tolerab. Effic.demonstrat.
   or Hb lev.(4,65 mmol/l), safety & effic.in childr.bel.12 yrs.not est.,   expos.incr.with concom.fluconazole, AUC, C max& C minsignific.low.   only for influ.virus. types A & B
                                                                        st
                                                                         nd
   concom. zalcitabine, safety in pregn.& lactat. not est.  by rifampicin, rifabutin conc.signific.incr., hypericum perfortum (St   Treatm: Start within 1 -2  day of sympt.onset. Adults & ado-
   Side-effects: Lact.acidos.(mostly women) & sev hepatomegaly with   John’s Wort) decr.conc. & result.sub-optimal lev., elev.trough conc.  lesc.&gt;13 yrs: 75 mg 2xdly.x5 days. Childr.over 40 kg or &gt;8 yrs:
   steatos.(incl.fatal cases), bld. dyscras., periph.neuropathy, headache,   with cimetidine, oestrog.lev.of OC’s signific.decr., plasma conc.of   75 mg cap.2xdly. (or one 30 mg cap.plus one 45 mg cap.) 2xdly as
   paraesthes., pancreatit., GI disturbs., skin rash, alopec., arthral.&   methadone decr.  alternat.to recom.oral susp.dos.
   musc.disords.incl. rhabdomyolys., malaise, fatig., fev.    Susp.childr.&gt;1 yr: &lt; 15 kg: 30 mg 2xdly x 5 days. &gt;15 -23 kg: 45
   Special precautions: Poss.contin.of HIV complicat. & opportunist   STOCRIN, MSD [P/S]  mg 2xdly x 5 days. &gt;23-40 kg: 60 mg 2xdly x 5 days. &gt;40 kg: 75 mg
   infects., ther.not proven to prev.transmiss., ren./hepat.impairm., adv.   Efavirenz.  2xdly x 5 days. Infts.6-12 mnths: 3 mg/kg 2xdly x 5 days dur. pan-
   cirrhot. liv.dis.due to chron.Hepatit.B infect., discont. use if pancreat./  Indications: In combinat.with other antiretrovir. agents for HIV-1   dem. influenza outbeak only.
   lact.acidos./ hepatotoxic. suspect., risk fact.for liv.dis.  infect.adults, adolesc.& childr.  Prophylax: Adults & adolesc: Follow.close contact: 75 mg once
   Drug interactions: Trimethoprim incr.plasma conc., intracell.phos-  (S4) TABS, 37/20.2.8/0628  dly x10 days start.within 2 days of expos. Dur.community outbreak:
   phorylat.of zalcitabine inhibit.  703318-001: 600 mg, 30, R328,69  75 mg once dly. Safety & effic. demonstrat.x6 wks. Protect.last.
                                Dosage: Admin.in combinat.with a protease inhibit.&/NRTI’s.   as long as dos.cont.
   SONKE LAMIVUDINE + ZIDOVUDINE, (Sonke) Ranbaxy [P/S]  Avoid admin.with a fatty meal as absorpt.incr., consid.bedt.dos.in   Childr &gt;1 yr: &gt;40 kg able to swallow caps.may receive prophylax.
   Lamivudine 150 mg, zidovudine 300 mg.  indiv. exper.CNS effs. Tabs are for indiv.greater/or equal to 40 kg.  with a 75 mg cap.(or one 30 mg cap.plus one 45 mg cap.) 1xdly
   Indications: HIV infect.when combinat.ther. reqd.  Adults: Recomm.dos: 600 mg once/day. Adolesc. & childr.17   for 10 days as alternat.to oral susp. Recom.prophylact.oral dose
   (S4) TABS, A40/20.2.8/0254   yrs.& und: Admin.to childr.able to swall. tabs. Recomm.once dly.  for children &gt;1 yr: &lt; 15 kg: 30 mg 1xdly x10 days. &gt;15 – 23 kg: 45
   707971-001: 60, R191,90      dos: 13-15 kg: 200 mg, 15-20 kg: 250 mg, ≥20-&lt;25 kg: 300 mg, 25-  mg 1xdly x10 days. &gt;23-40 kg: 60 mg 1xdly x 10 days. &gt;40 kg: 75
   Dosage: Admin.in combinat.with other ARV’s.  &lt;32,5 kg: 350 mg, 32,5-&lt;40 kg: 400 mg. Childr. greater / or equal   mg 1xdly x 10 days
   Adults & childr.over 12 yrs: 1 tab. 2xdly.  to 40 kg: 600 mg once dly.  Side effects: N&V, headache, pain, bronchit., sinusit., H.Simplex,
   Contra-indications: Abnorm.low neutrophil counts /haemoglobin   Contraindications: Pregn.(teratogen.in anim.), safety in lactat.&   nasopharyngit., URTI, flu, insomn., cough, nas.congest., sore throat,
   lev., concom.stavudine/ ribavirin & zalcitabine, safety of zidovudine   childr.und.3 yrs./weight &lt; 13 kg not est., concom.terfenadine/as-  rhinorrh., diarrh., abdom.pain, dyspeps., back pain, arthralg., myalg.,
   dur. 1  trimester pregn.unknown, safety in pregn.& lactat.not est.,  temizole/ cisapride /midazolam/ triazolam/ergot derivat.as ser./life   dysmenorrh., pyrex., flu-like illn., limb pain, dizzin., fatig., otit.med.,
     st
   Side-effects: Lact.acidos.& sev.hepatomegaly with steatos.most.  threat.adverse effs.poss., concom.St John’s Wort.  pneum., conjunctvit., earache, asthma, epistax., dermatit., lym-
   in women, bld.dyscras., periph. neuropathy, headache, paraesthes.,   Side effects: Rash, naus., CNS effs., psych. sympts. incl.psychos.  phadenopathy, tympan.membr. disord., neuropsych.events, allergy,
   pancreatit., GI disturbs., skin rash, alopec., arthral., musc.disords.,   like reacts./sev.ac.depress.& suicid., Stev.Johns.syndr., alcoh.in-  anaphylact. reacts., face oed., dermatit., skin rash, exzema, urticar,
   rhabdomyolysis, malaise, fatig., fev., anx., depress., insom., ment.  tol., allerg. reacts., abnorm.co-ordinat., asthen., hot flush., flu-like   erythema multforme, Stev.-John.Syndr., tox.epiderm.necrolys., hep-
   acuity loss, convuls., dizzin., somnol., dyspn., cough, chest & gen.  sympts., malaise, pain, syncope, GI disturbs. incl.gastroeosophag.  atit., elev.liv.enzymes, GI bleed partic.haemorrhag.colit.
   pain, nail/skin & oral mucosa pigmentat., urticar., prurit., sweat.,   reflux, tinnit., CV disords., hepatit., weight gain/loss, arthral./myal-  Warnings and special precautions: Neuropsych. events incl.
   myalg., asthen., myopathy, urin.freq., gynaecomast., chills, flu-like   gia, impot., libido chang., migraine, paraesthes., periph. neuropa-  convuls./abnorm.& inapprop. behav./disturbs.in conscious./ hallu-
   syndr., taste pervers.       thy, speech disords., trem., resp.disords., skin reacts., vis.& taste   cinat. & delirium report.dur.first few days of tak. Tamiflu in pts.with
   Special precautions: Opportunist.infects & other HIV compli-  disords., incr.tot.cholester.  influenza which in some cases result.in accident.self-injur.& death,
   cat.still poss., not proven to prev.transmiss., concom.self-admin.  Special precautions: Must not be used as monother./ add.on   not a substit. for influ.vaccinat., poss.season.vir. resist., dos.reduct.
   meds., monit.phenytoin bld.lev., monit.ren.funct.& haematolog.  as sole agent to fail.regim., consid. potent.vir.cross-resist., consid.  for creatinine clear.10-60 ml/ min, childr.und.1 yr.other than dur.a
   paramet.with potent.nephrotox./ myelosuppress.meds.& periodic.  simultan. discont. of all antiretrovir.meds.if combinat.regim. is intur-  pandem. influenza outbreak, safety in pregn.& lactat.not est., excret.
   dur.ther., unclear if adv.effs.are drug relat./part of underly. dis.pro-  rupt.because of suspect.intol.& restart medicat. at same time upon   in breast milk of rats theref.mothers should not breast feed, monit.
   cess, adv.cirrhot.liv.dis.due to chron.Hepatit.B infect., discont.use if   resolut.of intol. sympts., intermitt.monotherapy/sequent. reintrod-  pts.esp.paeds.& adolesc. careful.for abnorm.behav.
   pancreat. suspect.until.excl., liv.dis.risk fact., suspend.if clinic./lab.  uct. not advis., discont.in sev.rash & consid. prophylax.with appropr.
   find.suggest.of lact.acidos./ hepatotoxic. develop., mod.to sev.ren.  anthistam./ corticoster. proir to restart.treatm., liv.dis., pregn. test   TELATRI, (Sonke) Ranbaxy [P/S] &
   impairm., monit.haematolog.paramet., neutropen.incid. incr.in pres.  in women of childbear.bef.init.of treatm., use barrier contracept.in   Dolutegravir sod.equiv to dolutegravir 50 mg, lamivudine 300 mg,
   of low.vit. B12 lev.& concom. paracet.  combinat.with other methods, cholestr. monit., refer to prod.lit.when   tenofovir disoproxil fumarate 300 mg
   Drug interactions: Trimethoprim incr. lamivudine plasma lev.,   prescrib. other meds., lact.intol.  Indications: Treatm.of HIV infect.adults ≥ 18 yrs.
   meds.prim.eliminat.by hepat.metabol.esp.glucuronidat.may inhib.   Drug interactions: Addit.CNS effs.with concom. alcoh./psychoact.  (S4) TABS, 52/20.2.8/0719.718
   metabol., sub.therapeut./tox.phenytoin lev., zidovudine metabol.  drugs, plasma conc.of other compds. that are CYP3A4 substrat.poss.  3000571-001, 30, R499,95
   poss.alt.by meds.direct. inhibit. hepat.microsom.metabol./com-  decr., AUC & C max of indinavir/saquinavir & clarithromycin decr. theref.  Dosage: Consult.prod.info.of each therapeut. compon. of regim.bef.
   petit. glucuronidat. inhibit., poss.incr.toxic.risk with potent nephro-  consid.alternat., incr.freq.of S/E with ritonavir, methadone plasma   init.treatm., init.ther.by physic. exper.in HIV infect.managem. Adults:
   tox./myelosuppres.meds., in vitro ribavirin/stavudine is antagonist.,   lev.decr.result.in opiate withdr.signs in HIV infect.IV drug users, ex-  1 tab. once dly. Rifampicin decr.bld.lev.of dolutegravir & supplement.
   probenecid incr. zidovudine mean half-life & AUC, zidovudine’s AUC   pect. reduc.conc.with St John’s Wort.  dos.of dolutegravir poss.reqd.
   decr.by rifampicin           SYMMETREL, Novartis [P/S]     Contraindications: Ren.funct.impairm. (creatin. clear. &lt; 80 ml/
                                                              min), pregn.& lactat., women of child-bear. age not using highly ef-
   SONKE NEVIRAPINE, (Sonke) Ranbaxy.Ltd [P/S]  Amantadine HCl.  fect.contracept., concom. adefovir dipivoxil/dofetilide/pilsicainide
   Nevirapine                   Indications: Prevent.and or treatm.of influenza A virus flu.  / didanosine/ metformin, pts.&lt; 18 yrs., mod.to sev. hepat.impairm.
   Indications: In combinat.with at least 2 other antiretrov. agents   (S4) CAPS. A/20.2.8/768.  Side effects: Freq: Hyperlactataem., headache, insomn, cough,
   for HIV-I infect.            768243-009: 100 mg, 20, R276,64  nas.sympts., pneum., N&V, upper abdom. pain, diarrh., rash, alopec.,
   (S4) TABS, A10/20.2.8/0341   Dosage: Admin.with meals pref.in morn.& midd.  prurit., myalg., arthralg., musc.disord., fatig., malaise, asthen., pain,
   709533-001: 200 mg, 60, R142,00  Influenza A virus: Preventat.treatm.& treatm. Childr. 5-9 yrs:   back/chest pain, fev., dizzin., depress., anx., anorex., dyspeps., flatul.,
   Dosage: Adhere strict.to dos.dur.14 day lead-in period to reduc.  1 cap.dly. Childr. & adults 10-65 yrs: 1 cap. 2xdly. Adults over   abnorm.dreams, periph. neuropathy., proxim.tubulopathy, proteinur.,
   freq.of skin rash. Monit. clinic. chem. incl.LFT prior to & at interv.dur.   65 yrs: 1 cap dly. Prevent: When admin.with vaccine cont.treatm.   incr. creatin., ac.tubul.necros., nephrogen.diabet. insipid., hypophos-</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page314.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page310.html">310</a>&nbsp;&nbsp;&nbsp;<a href="page311.html">311</a>&nbsp;&nbsp;&nbsp;<a href="page312.html">312</a>&nbsp;&nbsp;&nbsp;<a href="page313.html">313</a>&nbsp;&nbsp;&nbsp;<a href="page314.html">314</a>&nbsp;&nbsp;&nbsp;<a href="page315.html">315</a>&nbsp;&nbsp;&nbsp;<a href="page316.html">316</a>&nbsp;&nbsp;&nbsp;<a href="page317.html">317</a>&nbsp;&nbsp;&nbsp;<a href="page318.html">318</a>&nbsp;&nbsp;&nbsp;<a href="page319.html">319</a>&nbsp;&nbsp;&nbsp;<a href="page320.html">320</a>
             </td>
             <td width="35%"><a href="page316.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page316.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
